EXEL vs TECH: fair value comparison
Exelixis, Inc. and Bio-Techne Corporation · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, TECH currently sits closer to the top of our discount ranking.
| EXEL | TECH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $55.06 | $72.35 |
| 12-month range | $37.18–$55.06 | $50.79–$72.14 |
| Sector rank | #48 of 113 Healthcare | #47 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | — | B |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Fairly Valued | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: EXEL fair value analysis · TECH fair value analysis